Can-Fite BioPharma Ltd.(CANF) Intrinsic Value & DCF Analysis (2026)
Current Price
$3.54
Last updated: May 08, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
Trend data unavailable
The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-2.26 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.54, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -15.77% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-2.26 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.54, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -15.77% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.Valuation Details
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Price moving to at least a mid-teens discount to fair value
- Improvement in ROIC versus WACC spread
- Meaningful shifts in the narrative score direction
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Can-Fite BioPharma Ltd.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Can-Fite BioPharma Ltd.Healthcare
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.